Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD7760
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AZD7760 is a monoclonal antibody developed by AstraZeneca for the prevention and treatment of staphylococcal infections, specifically targeting *Staphylococcus aureus* virulence factors. It acts as a bacterial virulence modulator, aiming to neutralize key pathogenic mechanisms of *S. aureus* rather than directly killing the bacteria. The drug is administered intravenously and has been evaluated in Phase I/II clinical trials for safety and pharmacokinetics in both healthy participants and patients with end-stage kidney disease receiving hemodialysis[2][5][7]. As of early 2025, it remains an investigational agent with no approved indications.
Beyond the preview
Go deeper on AZD7760.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD7760.